Metformin, pharmacological activators of AMPK by increasing the phosphorylation of PRKAA (Thr172), have been demonstrated to be able to prevent the progression of HF [41] and attenuated trastuzumab-induced cardiotoxicity [58]. This evidence concerns the gene PRKAA2 and hydrops fetalis.